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y~ertems~o~ after cardiac Transvaal- 
e of the most frequent adverse side 
,2). High loading and intenance 
been associated with increased 
nt systemic hypertensions varying 
frolm 40% to 90% among the studies G-5), aad with chronic 
renal insufficiency (6) These complications were less fre- 
quent before the i~~rod~ctio~ ~~~y~~ospori~e when Fatients 
were receiving azathioprine and prednisone only. ht that 
time, postoperative hypertension developed in ~20% of the 
heart transplant recipients (7). Although the exact mecha- 
nisms of cyclosporine-associated hypertension are still un- 
known, the fungal endeca ide is a potent renal vasocon- 
strictor (S), with dose 
Unopposed hypertension will, in turn, alter renal function or 
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impair ~ardioi/as~al~~r fu 
risk of left ~~atri~M~ar 
cyclo~~orine after the graft in heart trao§~lant 
osages: 2) the impact of by~e~e~sio~ on renal 
function: and 3) the potential relation between 
plant hypertension and left vemtri~ular by 
f these, $5 r~ci~ieat~ wit 
21 month follow-up after tra~sp~afltatioa were selected for 
the study. Their mean age was 48 -I IQ years. There were 69 
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qj,& 1. Clinical Characteristics of 57 Hypertensive and 28 
Nomotensive Heart Transplant Re lipients 
- 
Hypertensive Normotensive 
(n = 57) (n = 28) 
Age (~0 49 + 9 46 + 9 
Gender 47MllOF 22MibF 
Inidal cardiac disease 
lschemic cardiopathy 24 IO 
Idiopathic dilated cardiomyopathy 26 II 
Other 7 7 
Cold &hernia lime (min) ISI zk 51 130 2 41 Is 
men and 16 women. Ilnitial c~~rdiomyop~lthy was caused by 
coronary artery disease in 34 patients, idiopathic dilated 
card~omyop~tky in 37 and rheumatic heart discasc, congcn- 
ital heert disease or cardiac omyloidosis in 14. Donors and 
recipients wcrc metckcd for hcigkt. weight, ABQ blood 
roup and lymphocyte compatibility before orthotopic car- 
diac transplantation, The avenge ischemic time for the 
donor heart was defined by the time elapsing between 
donor aorta and releasing the recipient aorta. 
ppressive therapy. All patients received low 
suppressive therapy according to the following 
protocol: Cyclosporine was introduced on the third day after 
transplantation only if serum crentinine was S I.50 fimollliter 
at an initial dosage of 5 mg/kg per day. The daily dosage was 
progressively adjusted to obtain a trough serum cyclosyorinc 
level of 150 to 200 nglml during the first year after trans~laa- 
tation and IO to IS0 ng/ml thereafter, as measured by 
nonspecific r~~dioi~~munoassay (Snndoz) on plasm2 sepa- 
ose was tncreased to 2 a~~~~ per 
was adjusted to maintain a 
ml. Corticosteroid therapy 
d was tapered progres- 
dosage. of 0.2 mg/kg per 
then once a month during follow-up. Rejection 
severe rejection (increased inflammatory in~ltrate ~nc~adin~ 
neutrophiis, monuclear pyroninopki~ic cells, i 
orrhage and edema, myocyte necrosis). Gr 
was not treated. Grade 2 rejection was treated w!tk pulsed 
met~ylpredniso~one (I g ~atraveno~~s~y for 3 c~~~sec~tive 
days); grade 3 rejection with rabbit a~titkymocyt~~ globulins 
(2.5 mg/kg per day) and pulsed methyl~rednisoloae (I g/da 
intravenously) for 3 consecutive days: grads 4 rejection wit 
a 10 day course of Q T 3 (~~koc~oae, Cilag ~ak~~tori~s: 5 
mglday intrave~~usly~ and pulsed m~tkylpred~iso~one (I g 
iutr~~wc~lo~~s~y for 3 co~~s~~~~t~vc days). 
~~~~~n ul d 
wit mercury k 
~~rotk~~v sounds (an average of tkrcc 
supi~c rest for 10 ~~~11~. ~~stc~~~c kyp~~t~as~~~ was de 
if, at three separate rne~~s~~re~i~nts by tke same pkysi 
systolic or diastolic klo~d pr~ss~lr~, or both, was ~l~t~~~~ 
mm pig, rcsp~ctiv~~y, or if booted ~r~ss~lr~ was normal with 
the patient or at least two aatik 
to the Joint rationed Commi 
Antihypertensive agents presc 
derivatives and, in partic~~~ar, sic 
little pharmacoki~ctic 
giotensin~coave~in~ enzyme inhibitors (if s 
was <2OtI ~rno~~lit~~~, central-acting agents 
combinations of these 
determinations performed in the same laboratory. 
Posttransplarzt riskfacrors ojsystemic hyperfension were 
also recorded. We analyzed: I) weight gain after cardiac 
transplantation. expressed in kilograms; and 2) total number 
of 1 g intravenous bolus injections of methylprednisolone 
rcccived by each patient for treatment of acute rejection 
episodes from the day of transplantation to the time of onset 
of systemic hypertension. 
~e~~~~!~~/~c~io~~ was assessed using serum creatinine val- 
nd expressed in micram~les per liter. 
I variables fblood pressare valaes, pos~~ra~sp~an~ risk 
and serum creatinine) were recorded once a week 
the first posttransplant montk, then once a month 
the fir.;t year and once every 4 
during follow-up for every patient included in the study. 
Before cardiac transplantation, patients gave informed con- 
sent for the routine follow-up evaluation after transplanta- 
under stable hemodyaamic conditions; 2) i 
~at~oa after 6 months of follow-up; and 3) 
jncloded in the study. 
ressed as mean values 
crteasion and 28 rema~ncd mormoteasive after ca 
in the hypertensive and aormotensive groups (Table Il. Age, 
gender, initial cardiac disease and mean cold ischemia time 
were not significantly different between the two groups. 
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3. Echocardiographic Variables inthe Early (4 weeks), Intermediate (6 months) and Late 
t follow-up) Evaluations After Cardiac Transplantation n 42 Patients 
IVST LVEDD LVESD PWT FS - 
(mm) (mm) (mm) (mm) (%b) 
Early 
H (II = 28) 10.4 k 2.1 45.3 + 4.5 28.9 + 5.8 10.7 C!z 1.2 0.36 ” 0.09 
N (n = 14) 10.0 * 0.9 44.5 + 5.7 26.5 + 5.6 10.6 + 0.9 0.40 ?Iz 0.08 
Intermediate 
H (II = 28) IO.2 * I,9 47.2 + 5.2 30.9 * 5.6 IO.1 c 1.2 0.34 9 0.09 
N (fl = 14) 10.2 f I,3 46.1 * 5.6 31.3 I5.5 10.3 ,’ 1.6 0.32 z+z If&* 
LalC 
O.36 ” O.O8 
0.32 ” 0.05’ 
: H - hypertensive heart transplant recip~eut~~ 
IVST m interventricular scptal thickness: LVEDD and LVESD m lefi v~~lri~ul~~ end”d~~stoltE ond end-systolic 
dialaster, ~s~~tively; N = normoten?ivc heart transplant recipients; PWT = psslcrior wall tbickncss. 
first month after iransplantation (from 104 2 20 to I IO 2 25 
r)> At 6 months, serum creatinine had increased to
liliter (n = 19, one way analysis of variance: F 
I). There was no significant difference 
sive and normotensive patients when we 
comt_cued serum creatinine values from day 8 to the first and 
to the skth month (two way analysis of variance, p = NS). 
Serum creztinine remained relatively stable at I and 2 years 
a&s transplan!ation n both n serum 
ct~ininf :‘&cs were 164 * nsive (n 
v 66’) f .d 153 2 51 IwngUlit normotensive patients (n = 
i J) at 12 months, and 165 A 45 ~ollliter in 30 hypertensive 
~~~~ts and 191 A 59 ~olllitar in 9 normotensive patients 
lit 24 ~~~rnths after t~ns~la~tatiou ( = NS, inter- and 
to our selection 
to the presence orabsence 
nsplantation. Time of fol- 
imilar in both groups, with 
and 12 k 4.3 months for the 
e evaluation i  either hypertensive 
Early increased septal thickness 
th groups and remained stable 
t the evolution. Left ventricular posterior wall 
&kkeGw was present early after cardiac transplantation 
hypertensive group thro 
normotensive group, it 
(0.40 1: O.Og%) tointerm 
to the latest follow-up (0.32 It; 0. 
e@I vtmtrkdtw mass (Table 
trophy was present in both 
sivc a;id 186 2 57 
after cardiac tran 
elevated in both hy~rteasive and normote~sive patients 
until the end of follow-up ~va~~atiQa. 
Role of cycl rine. The use of cyclosporine isassoci- 
ated with a high incidence of new systemic hy~$~ension n 
patients undergoing any type of organ transplantation 
(IS.16). as well as in immunesuppressed patients without 
organ transplantation (19). This side effect was seen to 
develop early after cardiac transplantation n 60% to 93% of 
the recipients when they received cyclosporine on day of 
transplantation at high initial dosage (6 to 10 mgkg per day) 
Tabb 4. Left Ventricular Mass Evolution in 42 Patients 
Early Intermediate Late 
Hypertensive (n = 28) I%247 201 264 I99 2 49 
Normatensive in = 14) 186 2 57 I% + 61 193 + 39 
Total (II = 42) I93 * 50 197 _+ 45 
No significant difference was seen in left ventricular mass values (in g) 
during the enlire follow-up period in both groups of hypertensive and 
normotensive heart transplant recipients. 
studies will be necess 
roids in cyclosporine-associated hy~ertensio 
ese observations confirm and 
plant hypertension. This problem was emphasized by the 
fact that 71% of the hypertensive patients in our study 
developed new hypertension. However, the exact relation 
between cyclosporine toxicity and onset of by~erte~s~on 
after cardiac transplantation remaius to be determined. 
Cyclosporine may act directly on the a~er~oles to rak 
peripheral vascular esistance (21) and has direct potent 
~epbr~toxicity (8,22,23). 
Cyclosporinr ne~hroto.dciby wd relation lo hyprren- 
don. Cyclosporine nephrotoxkity has been clearly demon- 
strated by abundant reports (6.22-24) on the late onset of 
renal dysfunction. However, few studies have addressed the 
orine co~ce~t~atio~s 
unoassay. Further s 
te6hai~~e and tbe 
ific tool used to assess the s~ect~m 
of left ventricular hypertrophy ( 1. Its ~~ef~~~~~~ in 
tra~spiant recipients i now bei es~blisbed (10,261 
therefore designed the second p of the study to asse 
impact of hypertension on ~~sttraasp~a~t left ventricular 
ass. This was increased in our pa- 
e preservation f systolic functio 
193 sz 50 g early after cardiac 1
able 4). Iln normotensive 
ass values are 176 -t- 45 g 
51, with a mean of 150 k 
excess ~rl~e~e~~~e~t of a 
standardization f echocardiog~dp~~ic left v~~t~cMlar an& 
tomic measurements, mass vahtes are usually related to 
body surface area. Discrepancies between donors and reCiP 
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ients prevent the use of this index after cardiac transplanta- 
tion, and evaluation of left ventricular mass could not be 
indexed to body surf&ze area in our study. 
Thp ear/y increase in left venlricdar mass rmkd 
stable throughout the evolution and was similar in Patients 
with or without hypertension. Left ventricular hypertrophy 
was mainly due to an increase in left ventricular wall 
thickness because end-diastolic and end-systolic dimensions 
remained in the normal range. Hypertension itself was not 
~s~us~ble for the early development of left ventricular 
hy, Other factors ay be involved. ~iu~h~rnical 
s related to increasin uscle mass have been dem- 
ed after sudden incre in afterload (28. The @ally 
in WBII thickness can also be related in part tc 
nd interstitial edema secondary to ischcmia during 
~l~~~l~ntati~~n of the donor heart (29,301. However, no signif- 
icant correlation was found in the present study between 
mean cold ischemia time atrd the prcscnce of left ve~t~~cul~~r 
hy~~r~~hy or impaired contractility, or both. Early treat- 
men h blood pressure could explain 
Wit hy~~r~~hy observed in this 
did not observe any significant regression WI 
reported by others (3 I). 
~~~i~~~~ shorten@. This was observed at 
ation demonstrating enhanced contractility. 
This variable tended to decrease significantly throwgh the 
follow-up of normotensive patients, but did not vary in the 
p. Such variations can be linked to left 
pressures (32,131 and could explain the 
tween hypertensive and ~ormotensive 
nts. ~~emody~amic studies (34) have 
shown a relatively high prevalence of mild to moderate 
hemody~am~c abno~~l~ties in asyn~ptomatic heart trans. 
lant Ecipknts after I year. In that study (34). increases in 
~~rno~~~~ arterial, ~ulmon~y artWia\ 
~tri~uf~~ ~u~~d~~stu~i~ pressures WCE 
rn~t~rn~t~~ heart transplant recipients and re- 
tbn, systemic arterial hypertension or less well 
ors. The use of ~utihy~~ensiv~ drugs did not 
hemodynamic values in those patients (34). 
these observations could explain our results concerning 
tt ai. (101 did not obscrvc any variation of left vent~cu~a~ 
URNS or fmctioaal shortening, or both, during an acute 
tiQt episode withes the first posttra~s~~a~t months, 
(35) have shown an increase in left ventricular mass 
with r&c&n. In addition, a decrease in fractional 
& aftee I year has been shown to occur indepeo- 
den& of rejection (361. A recent study (26) documented a 
~tw~n impaired ventricular function, with a significant 
in DsPpler echocardiographic indexes of left ven- 
tricular filling and ejection, and indigence of ~eject~o 
Abnormal restrictive-constrictiv b~sio~o~y occurred 
approximately 15% of allograft recipients with impaired 
ventricular relaxation, altb~M~h left ventricular mass was rmt 
measured (26). 
Echocardiographic evaluation in our study was stormed 
only in the absence of a simultaneous 
confirmed by sim~ltaueous eo~omyo~ 
ever, potential acute rejection that may have 
tween the two ultrasound evaluations could not be r 
tility or the sustained increase 
fore, this factor cannot be rul 
cations of left v~nt~cular mass. 
well as of other 
o~~~~ut of hypertensi 
an early indicator of cyc 
an o~t~rna~ dosage ~~~rnM~ 
studies will be necessary to analyze the exact re~~t~~~ 
between cyclQsporine d~s~~~es wnrd drug toxicity to detect 
patients at risk for cyclosporine-associated h 
An early increase in MI ve~t~cu~ar mass 
sho~eni~~ was observed ufter heart transp 
ventricular hypertrophy was sustained in all 
Altho~~~h the pathophysiology of IeFt ventricula 
phy after cardiac transplantation still has to 
the presence of hypertension will contribute to 
tion. Early treatment of high blood pressure in s 
with iacreased cardiovascular risk factors after transplanta- 
tion might help to decrease morbidity and mortality. Future 
studies will help determine the optimal antihypertensive 
therapy in such henrt transplant recipients. 
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